Lifestyle interventions
Lifestyle interventions has been studied in 81 papers since 2014: 4 trials and 1 observational study in people, 73 reviews; 57 in the past year. The newest paper, Nov 19, 2026: “Recomendaciones sobre el estilo de vida. Actualización PAPPS 2026”.
81 papers study it30 findingsUpdated
Research on it is growing 82% faster than aging research as a whole: 81 papers in the latest year counted
20 new papers in 30 daysSee all 81 papers on lifestyle interventions
At a glance
The findings reach people, from one lab or study. 11 independent labs in 5 countries.
“No significant intervention effects on brain structural or vascular outcomes were found.”
1 of its findings points the other way.
- 11 independent labs in 5 countries
- 1 finding against
- Funders: National Institutes of Health and others
- 1 of 16 findings with company ties
- Human trial4
- Humans1
- In silico2
Studies in people
3 studies gave lifestyle interventions to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on NAD+ | Treated cohort | Nature metabolism, May 14, 2026 | |
no change: Has no effect on brain structural and vascular outcomes | Randomized trialone year | 134 peopleaged 60 to 80 yearsSCD participants | Aging clinical and experimental research, May 14, 2025 |
up: Raises the risk of mortality+28% relative risk, p < 0.00688 | Review of trials | 36 people pooledolder adultsOlder adults | medRxiv : the preprint server for health sciences, Sep 29, 2023 |
What did studies of lifestyle interventions find?
16Studies of lifestyle interventions measured 16 outcomes; the most studied is cardiovascular disease (3 studies).
Cardiovascular disease
downin humans3
3 studies
Cardiovascular disease
downin humans3
Lifestyle interventions decrease cardiovascular disease in humans.
Review
Lifestyle interventions decrease cardiovascular disease in older individuals with MetS.
Reviewin older individuals with MetS
Lifestyle interventions protect against cardiovascular disease in humans.
Review
Brain structural and vascular outcomes
no changein humans1
1 study
Brain structural and vascular outcomes
no changein humans1
Lifestyle interventions showed no clear effect on brain structural and vascular outcomes in humans.
Human trialone year
Lifestyle interventions showed no clear effect on brain structural and vascular outcomes in humans (subjective cognitive decline).
Human trialsubjective cognitive declinebrainone year
Cardiometabolic risk factors
upin humans1
1 study
Cardiometabolic risk factors
upin humans1
Lifestyle interventions improve cardiometabolic risk factors in humans (cardiovascular–kidney–metabolic syndrome).
Reviewcardiovascular–kidney–metabolic syndrome
DNAm-based measures of aging
no changein humans1
1 study
DNAm-based measures of aging
no changein humans1
Lifestyle interventions showed no clear effect on DNAm-based measures of aging in humans (Chronological-age clocks: SMD −0.04 (95% CI −0.31 to 0.24); phenotypic/mortality clocks: −0.17 (−0.42 to 0.09); DunedinPACE: −0.01 (−0.17 to 0.15)).
Reviewn = 1,675
Leptin
downin humans1
1 study
Leptin
downin humans1
Lifestyle interventions decrease leptin in humans (clinically defined metabolic syndrome) (WMD −4.38 ng/mL, 95% CI −6.20 to −2.56).
Reviewclinically defined metabolic syndrome
Adiponectin
upin humans1
1 study
Adiponectin
upin humans1
Lifestyle interventions increase adiponectin in humans (clinically defined metabolic syndrome) (WMD 0.85 μg/mL, 95% CI 0.14 to 1.55).
Reviewclinically defined metabolic syndrome
Telomere length
no changein humans1
1 study
Telomere length
no changein humans1
Lifestyle interventions showed no clear effect on telomere length in humans (cancer survivors).
Reviewcancer survivors
C-reactive protein
downin humans1
1 study
C-reactive protein
downin humans1
Lifestyle interventions decrease C-reactive protein in humans (−0.52 mg/ml, 95% CI −0.72 to −0.33).
Review
Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
Lifestyle interventions improve cognitive function in humans (mild cognitive impairment or subjective cognitive decline) (SMD 1.49, 95% CI 1.06 to 1.93).
Reviewmild cognitive impairment or subjective cognitive decline
NAD+
no changein humans1
1 study
NAD+
no changein humans1
Lifestyle interventions showed no clear effect on NAD+ in humans.
Human trialwhole blood
All 16Fewer
What is lifestyle interventions linked with?
10Studies link lifestyle interventions with 10 measures, among them mortality, Explicit inclusion of African immigrants and kidney-associated fat measures.
Mortality
downin humans1upin humans1RR 0.88
2 studies
Mortality
downin humans1upin humans1RR 0.88
Lifestyle interventions raise the risk of mortality in humans (+28% relative risk, p < 0.00688).
Human trialn = 36
Lifestyle interventions lower the risk of mortality in humans (RR 0.88).
Review
Explicit inclusion of African immigrants
mixedin humans1
1 study
Explicit inclusion of African immigrants
mixedin humans1
Lifestyle interventions are associated with explicit inclusion of African immigrants in humans (Lifestyle intervention trials targeting Black/African American adults in the US) (Only one of 43 eligible studies explicitly reported inclusion).
ReviewLifestyle intervention trials targeting Black/African American adults in the US
Kidney-associated fat measures
mixedin humans1
1 study
Kidney-associated fat measures
mixedin humans1
Lifestyle interventions are associated with kidney-associated fat measures in humans.
Reviewkidney-associated adipose tissue
Stroke
downin humans1RR 0.82
1 study
Stroke
downin humans1RR 0.82
Lifestyle interventions lower the risk of stroke in humans (RR 0.82).
Review
Cardiovascular mortality
downin humans1RR 0.84
1 study
Cardiovascular mortality
downin humans1RR 0.84
Lifestyle interventions lower the risk of cardiovascular mortality in humans (RR 0.84).
Review
Major adverse cardiovascular events
downin humans1RR 0.85
1 study
Major adverse cardiovascular events
downin humans1RR 0.85
Lifestyle interventions lower the risk of major adverse cardiovascular events in humans (RR 0.85).
Review
Anti-obesity medications
upin humans1
1 study
Anti-obesity medications
upin humans1
Anti-obesity medications are associated with lifestyle interventions in humans (adjunct to obesity management medications in Phase 3 trials).
Reviewadjunct to obesity management medications in Phase 3 trials
Stroke and recurrent stroke events
downin humans1
1 study
Stroke and recurrent stroke events
downin humans1
Lifestyle interventions are associated with stroke and recurrent stroke events in humans (primary and secondary stroke prevention).
Reviewprimary and secondary stroke prevention
Dementia
downin silico1
1 study
Dementia
downin silico1
Lifestyle interventions lower the risk of dementia in silico.
In silico
Alzheimer's disease
downin humans1
1 study
Alzheimer's disease
downin humans1
Lifestyle interventions lower the risk of Alzheimer's disease in humans.
Review
Funding
17 grants since 2016National Institute on Aging$9.7MNational Center for Chronic Disease Prev and Health Promo$3.1MNational Institute for Health Research£2.3M
National Center for Chronic Disease Prev and Health PromoNorthwestern University$820K2022–2027
National Center for Chronic Disease Prev and Health PromoResearch Triangle Institute$600K2022–2027
National Center for Chronic Disease Prev and Health PromoEmory University$820K2022–2027
National Center for Chronic Disease Prev and Health PromoUniversity of Michigan at Ann Arbor$820K2022–2027
Canada Foundation for Innovation | Fondation canadienne pour l'innovationMcGill University2026
Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older (PIVOT)
National Institute on AgingUniversity of Illinois Chicago$649K2022–2027
Tissue-Specific Modulation of mtDNA Mutations: Exploring Aging and Lifestyle Interventions
National Institute on AgingUniversity of Rhode Island$567K2026–2031
Norges ForskningsrådUniversitetet i OsloNOK 4.3M2025–2028
European CommissionCharokopeio Panepistimio€5.9M2024–2027
Canada Foundation for InnovationMcGill UniversityCA$448K2023